Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Januar 2026

Biotek-snakken — Januar 2026

Planlagt Fastgjort Låst Flyttet Biotek-snakken
66 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #35

    prøver at forstå PD-L! isuue mha Chatgpt. PD-L1–negative GEA has:
    worse baseline prognosis
    poor response to chemo and IO alone
    lower OS in the control arm
    That means:
    Small absolute improvements translate into very large hazard ratio gains
    HRs look dramatic because the comparator performs badly
    So in PD-L1–negative disease:
    Control arm does poorly
    Triplet arm does “less poorly”
    → HRs look spectacular

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #36

      This does not mean:
      zanidatamab + chemo is weak per se
      or that IO is somehow redundant in PD-L1–positive disease
      It means the biology of PD-L1–negative tumors creates more headroom for relative gains. ???

      1 Reply Last reply
      0
      • F Offline
        F Offline
        Fandel
        wrote on sidst redigeret af
        #37

        Godmorgen...

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #38

          Monte Rosa hentede lidt mere end først oplyst og til fine kurs 24.

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #39

            https://finance.yahoo.com/news/monte-rosa-therapeutics-announces-pricing-034900567.html

            1 Reply Last reply
            0
            • HenrikhotH Offline
              HenrikhotH Offline
              Henrikhot
              wrote on sidst redigeret af
              #40

              Egetis Therapeutics Er et interessant valg. De er lidt i samme situation som Hansa Biopharma, der har et lægemiddel godkendt i Eu er har indsendt markedf.godk. 19 dec 25. De vil få en voucher ved godkendelse ca q3-4, der vil hjælpe på økonomien.

              1 Reply Last reply
              0
              • F Offline
                F Offline
                Fandel
                wrote on sidst redigeret af
                #41

                Godmorgen...

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  LP90
                  wrote on sidst redigeret af
                  #42

                  Henrikhot jeg har den i 2 depoter tror du ikke de skal ud og hente mere kapital inden ??? det frygter jeg lidt ?

                  1 Reply Last reply
                  0
                  • HenrikhotH Offline
                    HenrikhotH Offline
                    Henrikhot
                    wrote on sidst redigeret af
                    #43

                    LP90 hvis alt går efter planen vil voucheren hjælpe deres økonomi rigtig meget. Måske de vil udnytte, hvis kursen stiger meget, til at hente peng ved emmision med knap så stor udvanding.Men det ville så være af strategiske årsager.

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      LP90
                      wrote on sidst redigeret af
                      #44

                      Henrikhot tak 🙂

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        Mads83
                        wrote on sidst redigeret af
                        #45

                        Curasight - Årets første, bedste nyhed: Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas.... / The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026. https://news.cision.com/curasight/r/curasight-announces-encouraging-preliminary-data-from-phase-1-

                        1 Reply Last reply
                        0
                        • DarvinD Offline
                          DarvinD Offline
                          Darvin
                          wrote on sidst redigeret af
                          #46

                          God (og forventet) nyhed Mads83. Det tegner godt. En start, men med fuld skrue. Tror fortsat på et hurtigt faseforløb frem mod godkendelse. Super effektiv og meget lidt indgribende fjernelse af tumorer.

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lexus
                            wrote on sidst redigeret af
                            #47

                            Håber det lykkes da det er virkelig frygtelig sygdom.

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lexus
                              wrote on sidst redigeret af
                              #48

                              Mads83 link viker ikke.

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                Mads83
                                wrote on sidst redigeret af
                                #49

                                @Lexus: tak - jeg prøver igen her: https://news.cision.com/curasight/r/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiop,c4291355

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mads83
                                  wrote on sidst redigeret af
                                  #50

                                  nb, jeg fandt desuden denne artikel (betalt?) for et par dage siden; runder fint casen - og potentialet - op her i forbindelse med JP Morgan Health konferencen: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week?fbclid=IwY2xjawPS9-hleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeUdwZash-yYGoRL6j3W1Bi7FA9rJPtRbIg2qr1_oHaorynn2gRNu4S0gKuE8_aem_ajOA-UEHPCefwZdvF9dX7A

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lexus
                                    wrote on sidst redigeret af
                                    #51

                                    Mads tak for det.

                                    1 Reply Last reply
                                    0
                                    • T Offline
                                      T Offline
                                      Thesis
                                      wrote on sidst redigeret af
                                      #52

                                      Ny aktieanalys af Pila Pharma med kursmål 6,3 SEK (base) og 10,6 SEK (bull). ”Analyst Group estimates that the Company signs a licensing agreement with a partner in year 2028, following completed phase IIa studies in obesity and type 2 diabetes, with a deal value of USD 300m.”
                                      https://analystgroup.se/wp-content/uploads/2026/01/Analyst-Group-Pila-Pharma-ENG.pdf

                                      1 Reply Last reply
                                      0
                                      • HenrikhotH Offline
                                        HenrikhotH Offline
                                        Henrikhot
                                        wrote on sidst redigeret af
                                        #53

                                        https://www.tradingview.com/news/reuters.com,2026:newsml_TUCBVRYCG:0-egetis-therapeutics-chairman-acquires-shares/ Insiderhandel i Egetis før vigtige begivenheder.

                                        1 Reply Last reply
                                        0
                                        • F Offline
                                          F Offline
                                          Fandel
                                          wrote on sidst redigeret af
                                          #54

                                          Godmorgen...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper